Allogene Therapeutics, Inc.
ALLO
$2.13
$0.073.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.61M | -38.81M | -41.40M | -50.94M | -59.73M |
| Total Depreciation and Amortization | 2.87M | 3.06M | 3.10M | 3.11M | 3.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.45M | 8.36M | 8.76M | 11.04M | 12.00M |
| Change in Net Operating Assets | 18.37M | -202.00K | -145.00K | -2.24M | -8.29M |
| Cash from Operations | -12.91M | -27.60M | -29.69M | -39.03M | -52.93M |
| Capital Expenditure | -9.00K | 0.00 | -243.00K | -44.00K | -99.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.58M | 33.61M | 12.18M | 43.88M | 6.28M |
| Cash from Investing | -29.59M | 33.61M | 11.94M | 43.84M | 6.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 21.12M | 7.86M | 3.24M | 1.51M | 10.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 3.56M | 3.35M |
| Cash from Financing | 21.12M | 7.86M | 3.24M | 5.07M | 13.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.38M | 13.87M | -14.52M | 9.88M | -32.76M |